PL366885A1 - Method for manufacturing crystalline form alpha of additive salt of metanesulphonic acid and 4-(4-methylpiperazin-1-yl methyl)-n-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-yl amine] phenyl] benzamide - Google Patents

Method for manufacturing crystalline form alpha of additive salt of metanesulphonic acid and 4-(4-methylpiperazin-1-yl methyl)-n-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-yl amine] phenyl] benzamide

Info

Publication number
PL366885A1
PL366885A1 PL04366885A PL36688504A PL366885A1 PL 366885 A1 PL366885 A1 PL 366885A1 PL 04366885 A PL04366885 A PL 04366885A PL 36688504 A PL36688504 A PL 36688504A PL 366885 A1 PL366885 A1 PL 366885A1
Authority
PL
Poland
Prior art keywords
methyl
methylpiperazin
benzamide
pyrimidin
pyridin
Prior art date
Application number
PL04366885A
Other languages
Polish (pl)
Other versions
PL216883B1 (en
Inventor
Wojciech Szczepek
Dorota Samson-Łazińska
Bogdan Zagrodzki
Magdalena Glice
Wioleta Maruszak
Katarzyna Korczak
Łukasz Kaczmarek
Wiesław Szelejewski
Original Assignee
Instytut Farmaceutyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instytut Farmaceutyczny filed Critical Instytut Farmaceutyczny
Priority to PL366885A priority Critical patent/PL216883B1/en
Priority to UAA200611573A priority patent/UA84462C2/en
Priority to US10/599,461 priority patent/US7732601B2/en
Priority to PCT/PL2005/000024 priority patent/WO2005095379A2/en
Priority to EP05731354A priority patent/EP1742933A2/en
Publication of PL366885A1 publication Critical patent/PL366885A1/en
Priority to IL178097A priority patent/IL178097A/en
Publication of PL216883B1 publication Critical patent/PL216883B1/en

Links

PL366885A 2004-04-02 2004-04-02 Method for manufacturing crystalline form Ó of additive salt of metanesulphonic acid and 4-(4-methylpiperazin-1-yl methyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-yl amine] phenyl] benzamide PL216883B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL366885A PL216883B1 (en) 2004-04-02 2004-04-02 Method for manufacturing crystalline form Ó of additive salt of metanesulphonic acid and 4-(4-methylpiperazin-1-yl methyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-yl amine] phenyl] benzamide
UAA200611573A UA84462C2 (en) 2004-04-02 2005-02-04 Crystalline polymorphs of methanesulfonic acid addition salts of imatinib
US10/599,461 US7732601B2 (en) 2004-04-02 2005-04-02 Crystalline polymorphs of methanesulfonic acid addition salts of Imatinib
PCT/PL2005/000024 WO2005095379A2 (en) 2004-04-02 2005-04-02 Crystalline methanesulfonic acid addition salts of imatinib
EP05731354A EP1742933A2 (en) 2004-04-02 2005-04-02 Crystalline methanesulfonic acid addition salts of imatinib
IL178097A IL178097A (en) 2004-04-02 2006-09-14 Process for preparing isolated alpha-crystal form of methanesulfonic acid addition salts of imatinib

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL366885A PL216883B1 (en) 2004-04-02 2004-04-02 Method for manufacturing crystalline form Ó of additive salt of metanesulphonic acid and 4-(4-methylpiperazin-1-yl methyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-yl amine] phenyl] benzamide

Publications (2)

Publication Number Publication Date
PL366885A1 true PL366885A1 (en) 2005-10-03
PL216883B1 PL216883B1 (en) 2014-05-30

Family

ID=36645532

Family Applications (1)

Application Number Title Priority Date Filing Date
PL366885A PL216883B1 (en) 2004-04-02 2004-04-02 Method for manufacturing crystalline form Ó of additive salt of metanesulphonic acid and 4-(4-methylpiperazin-1-yl methyl)-N-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-yl amine] phenyl] benzamide

Country Status (1)

Country Link
PL (1) PL216883B1 (en)

Also Published As

Publication number Publication date
PL216883B1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
TWI347186B (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide
WO2005095379A3 (en) Crystalline methanesulfonic acid addition salts of imatinib
IL223350A0 (en) Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
ZA200804030B (en) Improved process for the preparation of 4-(benzimidazolylmethylamino)benzamides and the salts thereof
DK1794126T3 (en) Crystalline form of N - (- 4-fluorobenzyl) -N- (1-methylpiperidin-4-yl) -N '- (4- (2-methylpropyloxy) phenylmethyl) carbamide hemitartrate
IL186820A0 (en) Inhibitors of microsomal triglyceride transfer protein and apo-b secretion
IL164678A (en) High drug load tablet comprising 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide or phamaceutically acceptable salt thereof and process for its preparation
ZA200801854B (en) Method of preparing esomeprazole and salts thereof
AP2470A (en) Novel phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase
UY29766A1 (en) CRYSTAL SHAPES DELTA AND EPILON MESILATE IMATINIB
NO20054763D0 (en) Salts of clopidogrel and process for preparation
IL181169A0 (en) Trifluoromethyl substituted benzamides as kinase inhibitors
ZA200703440B (en) Novel crystalline form of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenthyl)-piperazine-1-yl]-methanone hydrochloride
WO2009065910A3 (en) Acid addition salts of imatinib and formulations comprising the same
PL1833810T3 (en) Crystalline modifications of n-alpha-(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino-(l)-phenylalanine-4-ethoxycarbonylpiperazide and/or salts thereof
IL180486A0 (en) Salts of benzimidazole derivative with amines and process for production thereof
DE602005007871D1 (en) 8-HYDROXY-5-E (-HYDROXY-2-AEE (1R) -2- (4-METHOXYPHENYL) -1-METHYLETHYLENE AMINO OETHYL-2 (1H) -CHINOLINONE MONOHYDROCHLORIDE IN CRYSTALLINE FORM AND METHOD OF MANUFACTURING THEREOF
PL366885A1 (en) Method for manufacturing crystalline form alpha of additive salt of metanesulphonic acid and 4-(4-methylpiperazin-1-yl methyl)-n-[4-methyl-3-[(4-pyridin-3-yl)pyrimidin-2-yl amine] phenyl] benzamide
ZA200705073B (en) 4-(4-(imidazol-4-yl)pyrimidin-2-ylamino) benzamides as CDK inhibitors
PL374074A1 (en) Method for the manufacture of crystalline 4-(4-methyl piperazine-1-yl)-N-[4-methyl-3-[(4-pyridine-3-yl)pyrymidine-2-yl amine]benzamide metylmonomesilane Ó
PL387516A1 (en) Pharmaceutical composition containing 4-[(4-metyl piperazine-1-yl)methyl]-N-[4-methyl-3-[(4-pyridine-3-yl pyrimidin-2-yl)amino]phenyl]benzamide, method of its manufacturing and the forms of the medicine containing this composition
DE60318319D1 (en) PROCESS FOR PREPARING MODIFICATION I OF N- (1-METHYLETHYLAMINOCARBONYL) -4- (3-METHYLPHENYLAMINO) -3PYRIDINSULFONAMIDE
UY28498A1 (en) CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINAMINE DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND USE.
SI1487424T1 (en) 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl)-benzamide for treating ang ii-mediated diseases
PL377984A1 (en) Method for the manufacture of N- (5- amino-2-methylo phenyl) -4- (3-pirydylo) - 2 - pyrimide amine

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20130402